4.7 Article

Barriers to mental health treatment: results from the WHO World Mental Health surveys

Journal

PSYCHOLOGICAL MEDICINE
Volume 44, Issue 6, Pages 1303-1317

Publisher

CAMBRIDGE UNIV PRESS
DOI: 10.1017/S0033291713001943

Keywords

Continuity; mental health care; treatment seeking

Funding

  1. National Institute of Mental Health (NIMH) [R01 MH070884]
  2. John D. and Catherine T. MacArthur Foundation
  3. Pfizer Foundation
  4. US Public Health Service [R13-MH066849, R01-MH069864, R01 DA016558]
  5. Fogarty International Center [FIRCA R03-TW006481]
  6. Pan American Health Organization
  7. Eli Lilly and Company
  8. Ortho-McNeil Pharmaceutical
  9. GlaxoSmithKline
  10. Bristol-Myers Squibb
  11. State of Sao Paulo Research Foundation (FAPESP) Thematic Project [03/00 204-3]
  12. Ministry of Health
  13. National Center for Public Health Protection
  14. Shenzhen Bureau of Health
  15. Shenzhen Bureau of Science, Technology and Information
  16. Ministry of Social Protection
  17. Saldarriaga Concha Foundation
  18. European Commission [QLG5-1999-01042, SANCO 2004 123, EAHC20081308]
  19. Piedmont Region (Italy)
  20. Fondo de Investigacion Sanitaria
  21. Instituto de Salud Carlos III, Spain [FIS 00/0028]
  22. Ministerio de Ciencia y Tecnologia, Spain [SAF 2000-158-CE]
  23. Departament de Salut, Generalitat de Catalunya, Spain
  24. Instituto de Salud Carlos III [CIBER CB06/02/0046, RETICS RD06/0011 REM-TAP]
  25. WHO/Directorate General of Health Services (DGHS)
  26. United Nations Development Group Iraq Trust Fund (UNDG ITF)
  27. Israel National Institute for Health Policy and Health Services Research
  28. National Insurance Institute of Israel
  29. Grant for Research on Psychiatric and Neurological Diseases and Mental Health from the Japan Ministry of Health, Labor and Welfare [H13-SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-013]
  30. Lebanese Ministry of Public Health
  31. WHO (Lebanon)
  32. National Institute of Health/Fogarty International Center [R03 TW006481-01]
  33. Sheikh Hamdan Bin Rashid Al Maktoum Award for Medical Sciences
  34. AstraZeneca
  35. Eli Lilly
  36. Hikma Pharm
  37. Pfizer
  38. Roche
  39. Sanofi-Aventis
  40. Servier
  41. Novartis
  42. National Institute of Psychiatry Ramon de la Fuente [INPRFMDIES 4280]
  43. National Council on Science and Technology [CONACyT-G30544-H]
  44. Pan American Health Organization (PAHO)
  45. New Zealand Ministry of Health
  46. Alcohol Advisory Council
  47. Health Research Council
  48. WHO (Geneva)
  49. WHO (Nigeria)
  50. Federal Ministry of Health, Abuja, Nigeria
  51. Health and Social Care Research and Development Division of the Public Health Agency
  52. Champalimaud Foundation
  53. Gulbenkian Foundation
  54. Foundation for Science and Technology (FCT)
  55. Ministry of Public Health
  56. Eli Lilly Romania SRL
  57. South African Department of Health
  58. University of Michigan
  59. US National Institute of Mental Health [RO1-MH61905]
  60. NIMH [U01-MH60220]
  61. Substance Abuse and Mental Health Services Administration (SAMHSA)
  62. Robert Wood Johnson Foundation (RWJF) [044780]
  63. John W. Alden Trust

Ask authors/readers for more resources

Background. To examine barriers to initiation and continuation of mental health treatment among individuals with common mental disorders. Method. Data were from the World Health Organization (WHO) World Mental Health (WMH) surveys. Representative household samples were interviewed face to face in 24 countries. Reasons to initiate and continue treatment were examined in a subsample (n=63678) and analyzed at different levels of clinical severity. Results. Among those with a DSM-IV disorder in the past 12 months, low perceived need was the most common reason for not initiating treatment and more common among moderate and mild than severe cases. Women and younger people with disorders were more likely to recognize a need for treatment. A desire to handle the problem on one's own was the most common barrier among respondents with a disorder who perceived a need for treatment (63.8%). Attitudinal barriers were much more important than structural barriers to both initiating and continuing treatment. However, attitudinal barriers dominated for mild-moderate cases and structural barriers for severe cases. Perceived ineffectiveness of treatment was the most commonly reported reason for treatment drop-out (39.3%), followed by negative experiences with treatment providers (26.9% of respondents with severe disorders). Conclusions. Low perceived need and attitudinal barriers are the major barriers to seeking and staying in treatment among individuals with common mental disorders worldwide. Apart from targeting structural barriers, mainly in countries with poor resources, increasing population mental health literacy is an important endeavor worldwide.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available